USA - engelsk - NLM (National Library of Medicine)

leading pharma, llc - leucovorin calcium (unii: rpr1r4c0p4) (leucovorin - unii:q573i9dvlp) - leucovorin calcium tablets are indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. leucovorin is improper therapy for pernicious anemia and other megaloblastic anemias secondary to the lack of vitamin b12 . a hematologic remission may occur while neurologic manifestations continue to progress.

USA - engelsk - NLM (National Library of Medicine)

proficient rx lp - leucovorin calcium (unii: rpr1r4c0p4) (leucovorin - unii:q573i9dvlp) - leucovorin calcium tablets are indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. leucovorin is improper therapy for pernicious anemia and other megaloblastic anemias secondary to the lack of vitamin b12 . a hematologic remission may occur while neurologic manifestations continue to progress.

Malaysia - engelsk - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

pahang pharmacy sdn. bhd. - leucovorin calcium/calcium folinate -

Malaysia - engelsk - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

hospira malaysia sdn bhd - leucovorin calcium/calcium folinate -

Australia - engelsk - Department of Health (Therapeutic Goods Administration)

pfizer australia pty ltd - calcium folinate, quantity: 54 mg (equivalent: folinic acid, qty 50 mg) - injection, solution - excipient ingredients: sodium chloride; water for injections - neutralising the immediate toxic effects of folic acid antagonists, eg methotrexate. treatment of megaloblastic anaemias due to folic acid deficiency, eg in sprue, malnutrition, pregnancy, infancy, liver disease and malabsorption syndromes. folinic acid rescue, ie using calcium folinate in conjunction with folic acid antagonists, eg methotrexate, to minimise systemic toxicity. indications as at 13 jan 05 : leucovorin calcium has shown good results in the treatment of certain megaloblastic anaemias resulting from folic acid deficiency. this mainly occurs in infants, during pregnancy, in malabsorption syndromes, liver diseases, sprue and malnutrition. it is not more effective than folic acid for these conditions. leucovorin calcium has also shown good results in reducing the toxicity and circumventing the effect of folic acid antagonists, if therapeutically desired.

Israel - engelsk - Ministry of Health

abic marketing ltd, israel - calcium folinate - solution for injection - calcium folinate 10.8 mg/ml - calcium folinate - calcium folinate - to diminish the toxicity and counteract the action of folic acid antagonists in cytotoxic therapy. as leucovorin-fluorouracil chemotherapy combination for cancer treatment.

Malaysia - engelsk - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

fresenius kabi malaysia sdn. bhd - leucovorin calcium/calcium folinate -

USA - engelsk - NLM (National Library of Medicine)

hikma pharmaceuticals usa inc. - levoleucovorin calcium (unii: 778xl6vbs8) (levoleucovorin - unii:990s25980y) - levoleucovorin 50 mg in 5 ml - levoleucovorin for injection is indicated for: - rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. - diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. - the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. limitations of use levoleucovorin for injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin b12, because of the risk of progression of neurologic manifestations despite hematologic remission. levoleucovorin for injection is contraindicated in patients who have had severe hypersensitivity to leucovorin products, folic acid or folinic acid [see adverse reactions (6.2)] . risk summary there are limited data with levoleucovorin for injection use in pregnant women. animal reproduction studies have not been conducted with levoleucovorin. levoleucovorin is administered in combination

USA - engelsk - NLM (National Library of Medicine)

amneal pharmaceuticals llc - levoleucovorin calcium (unii: 778xl6vbs8) (levoleucovorin - unii:990s25980y) - levoleucovorin 50 mg - levoleucovorin for injection is indicated for: - rescue after high-dose methotrexate therapy in adult and pediatric patients with osteosarcoma. - diminishing the toxicity associated with overdosage of folic acid antagonists or impaired methotrexate elimination in adult and pediatric patients. - the treatment of adults with metastatic colorectal cancer in combination with fluorouracil. limitations of use levoleucovorin for injection is not indicated for pernicious anemia and megaloblastic anemia secondary to the lack of vitamin b12 , because of the risk of progression of neurologic manifestations despite hematologic remission. levoleucovorin for injection is contraindicated in patients who have had severe hypersensitivity to leucovorin products, folic acid or folinic acid [see adverse reactions (6.2)] . risk summary there are limited data with levoleucovorin use in pregnant women. animal reproduction studies have not been conducted with levoleucovorin. levoleucovorin is administered in combination with methotr

USA - engelsk - NLM (National Library of Medicine)

major pharmaceuticals - leucovorin calcium (unii: rpr1r4c0p4) (leucovorin - unii:q573i9dvlp) - leucovorin is indicated to diminish the toxicity and counteract the effects of impaired methotrexate elimination and of inadvertent overdosages of folic acid antagonists. leucovorin is improper therapy for pernicious anemia and other megaloblastic anemias secondary to the lack of vitamin b12 . a hematologic remission may occur while neurologic manifestations continue to progress.